BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

597 related articles for article (PubMed ID: 32951338)

  • 1. Predictive value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography for PD-L1 expression in non-small cell lung cancer: A systematic review and meta-analysis.
    Seol HY; Kim YS; Kim SJ
    Thorac Cancer; 2020 Nov; 11(11):3260-3268. PubMed ID: 32951338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive Value of 18F-Fluorodeoxyglucose Positron Emission Tomography or Positron Emission Tomography/Computed Tomography for Assessment of Occult Lymph Node Metastasis in Non-Small Cell Lung Cancer.
    Seol HY; Kim YS; Kim SJ
    Oncology; 2021; 99(2):96-104. PubMed ID: 32980838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic test accuracy of
    Seol HY; Kim YS; Kim SJ
    Clin Radiol; 2021 Nov; 76(11):863.e19-863.e25. PubMed ID: 34261597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Construction of A Nomogram Prediction Model for PD-L1 Expression 
in Non-small Cell Lung Cancer Based on 18F-FDG PET/CT Metabolic Parameters].
    Hao L; Wang L; Zhang M; Yan J; Zhang F
    Zhongguo Fei Ai Za Zhi; 2023 Nov; 26(11):833-842. PubMed ID: 38061885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of 18F-Fluorodeoxyglucose Positron Emission Tomography or Positron Emission Tomography/Computed Tomography for the Detection of Recurrent Disease after Treatment of Malignant Melanoma.
    Lee JW; Nam SB; Kim SJ
    Oncology; 2019; 97(5):286-293. PubMed ID: 31437839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standardized 18F-FDG PET/CT radiomic features provide information on PD-L1 expression status in treatment-naïve patients with non-small cell lung cancer.
    Zhang R; Hohenforst-Schmidt W; Steppert C; Sziklavari Z; Schmidkonz C; Atzinger A; Kuwert T; Klink T; Sterlacci W; Hartmann A; Vieth M; Förster S
    Nuklearmedizin; 2022 Oct; 61(5):385-393. PubMed ID: 35768005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic performance of F-18 FDG PET/CT for prediction of KRAS mutation in colorectal cancer patients: a systematic review and meta-analysis.
    Kim SJ; Pak K; Kim K
    Abdom Radiol (NY); 2019 May; 44(5):1703-1711. PubMed ID: 30603881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can
    Du B; Wang S; Cui Y; Liu G; Li X; Li Y
    BMJ Open; 2021 Jun; 11(6):e044313. PubMed ID: 34103313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 18F-FDG PET/CT and whole-body MRI diagnostic performance in M staging for non-small cell lung cancer: a systematic review and meta-analysis.
    Machado Medeiros T; Altmayer S; Watte G; Zanon M; Basso Dias A; Henz Concatto N; Hoefel Paes J; Mattiello R; de Souza Santos F; Mohammed TL; Verma N; Hochhegger B
    Eur Radiol; 2020 Jul; 30(7):3641-3649. PubMed ID: 32125513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on
    Takada K; Toyokawa G; Okamoto T; Baba S; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Honda H; Oda Y; Maehara Y
    Cancer Med; 2017 Nov; 6(11):2552-2561. PubMed ID: 28980429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is Delayed Image of 18F-FDG PET/CT Necessary for Mediastinal Lymph Node Staging in Non-Small Cell Lung Cancer Patients?
    Lee SW; Kim SJ
    Clin Nucl Med; 2022 May; 47(5):414-421. PubMed ID: 35234195
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Hu B; Chen W; Zhang Y; Shi H; Cheng D; Xiu Y
    Ann Nucl Med; 2020 May; 34(5):322-328. PubMed ID: 32130663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between PD-L1 Expression and Metabolic Activity on
    Takada K; Toyokawa G; Tagawa T; Kohashi K; Akamine T; Takamori S; Hirai F; Shoji F; Okamoto T; Oda Y; Maehara Y
    Anticancer Res; 2017 Dec; 37(12):7073-7082. PubMed ID: 29187498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD147-mediated glucose metabolic regulation contributes to the predictive role of
    Li X; Fu Q; Zhu Y; Wang J; Liu J; Yu X; Xu W
    Mol Carcinog; 2019 Feb; 58(2):247-257. PubMed ID: 30320488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Value of
    Vekens K; Everaert H; Neyns B; Ilsen B; Decoster L
    Clin Lung Cancer; 2021 Sep; 22(5):432-440. PubMed ID: 33879398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance of F-18 FDG PET/CT for predicting malignant potential of gastrointestinal stromal tumors: A systematic review and meta-analysis.
    Kim SJ; Lee SW
    J Gastroenterol Hepatol; 2018 Mar; 33(3):576-582. PubMed ID: 28994187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between SP142 PD-L1 Expression and
    Zhao L; Liu J; Shi J; Wang H
    Contrast Media Mol Imaging; 2020; 2020():2010924. PubMed ID: 32765198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The correlation between PD-L1 expression and metabolic parameters of
    Xu X; Li J; Yang Y; Sang S; Deng S
    Clin Imaging; 2022 Sep; 89():120-127. PubMed ID: 35797878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between
    Zhao L; Liu J; Wang H; Shi J
    Br J Radiol; 2021 Mar; 94(1119):20200397. PubMed ID: 33492995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic test accuracies of F-18 FDG PET/CT for prediction of microvascular invasion of hepatocellular carcinoma: A meta-analysis.
    Kim K; Kim SJ
    Clin Imaging; 2021 Nov; 79():251-258. PubMed ID: 34157501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.